SEC Form 4 · accession 0001144204-16-095054
Aevi Genomic Medicine, Inc. · GNMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Garry Arthur Neil
Officer — Chief Scientific Officer
Period of report
Apr 15, 2016
Accepted (ET)
Apr 19, 2016 · 4:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001138776
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option Award (right to buy)F1 | $4.83 | Apr 15, 2016 | A | 200,000 | A | — | Apr 15, 2026 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1The option award vests in three equal installments on April 15, 2017, 2018 and 2019.